SciELO - Scientific Electronic Library Online

 
vol.70 issue4Experimental encephalitis caused by Taenia crassiceps cysticerci in miceThe expanding spectrum of clinically-distinctive, immunotherapy-responsive autoimmune encephalopathies author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Arquivos de Neuro-Psiquiatria

Print version ISSN 0004-282X

Abstract

DUTRA, Lívia Almeida et al. Neurosarcoidosis: guidance for the general neurologist. Arq. Neuro-Psiquiatr. [online]. 2012, vol.70, n.4, pp. 293-299. ISSN 0004-282X.  http://dx.doi.org/10.1590/S0004-282X2012000400014.

Neurosarcoidosis (NS) more commonly occurs in the setting of systemic disease. The diagnosis is based on a clinical history suggestive of NS, presence of noncaseating granulomas, and supportive evidence of sarcoid pathology, laboratory, and imaging studies. NS could involve any part of the nervous system and often demands high doses of steroids for symptom control. It presents low response to isolated steroids administration and frequently requires immunosuppressive agents. In NS, lymphocytes are polarized toward an excessive Th1 response, leading to overproduction of TNF-alpha and INF-gama, as well as lL-2 and IL-15. Infliximab, a chimeric monoclonal antibody that neutralizes the biological activity of TNF-alpha, is a new option in the NS treatment. We revised pathophysiology, clinical manifestations, diagnostic work up, and treatment of NS as guidance for the general neurologist.

Keywords : sarcoidosis; neurosarcoidosis; methotrexate; azathioprine; cyclophosphamide; infliximab.

        · abstract in Portuguese     · text in English     · pdf in English